Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Accuracy of Transcranial Colour Coded Duplex in Comparing With CT Angiography

NCT06920303 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-05-01
Last updated
2025-05-13

Condition(s) studied

Ischemic Stroke, Acute

Investigational drug(s) / intervention(s)

transcranial colour coded duplex

transcranial colour coded duplex: transcranial colour coded duplex is good non invasive tool in detect velocity and obstructions of intracranial arteries

Study summary

Investigator will compare accuracy of transcranial colour coded duplex with CT angiography in detecting arterial obstructions in patients presenting or with history of cerebrovascular ischemic strokes

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients who have acute ischemic strokes or transient ischemic attacks . Exclusion Criteria: 1. Patients with history of cardiac arrhythmia or discovered recently or known rheumatic heart disease. 2. Patients with history of autoimmune diseases. 3. Patients with space occupying lesion or hemorrhage in Ct brain. 4. Pregnant female. 5. Patients who refuse to participate in the study. 6. Patients who have history of allergy or developed acute kidney injury during previous dye injection. 7. Patients who have chronic kidney disease. 8. Premorbid neurological disorder (myopathy, multiple sclerosis) on neurological examination or previous investigations. 9. Inability to achieve safe vascular access. 10. Patients with insufficient temporal acoustic window.

Primary outcome measure(s)

  • detect accuracy of transcranial color coded duplex compared with CT angiography in diagnosing arterial obstructions in acute ischemic stroke — one year after enrolling one hundred cases
    investigator will detect if transcranial color coded duplex can be used for diagnosing arterial obstructions in acute ischemic stroke by measuring the peak systolic velocity of different intracranial arteries, investigator will compare with CT angiography imaging results to assess the accuracy of transcranial color coded duplex in diagnosis of acute ischemic stroke.

Trial sites (1)

FacilityCityRegionStatus
Sohag university hospital Sohag Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06920303 on ClinicalTrials.gov ↗ ← All trials in Egypt